Andere Sprachen Terns Pharmaceuticals, Inc.

Aktien

A2QNWR

US8808811074

TERN

Realtime-Estimate Cboe BZX Andere Börsenplätze 18:22:28 31.05.2024			% 5 Tage	% 1. Jan.
6,385 ^USD	-9,05 %		+7,00 %	-1,08 %

13.05.	Terns Pharmaceuticals, Inc. meldet Ergebnis für das erste Quartal zum 31. März 2024	CI
08.05.	Terns Pharmaceuticals, Inc. kündigt Änderungen in der Geschäftsführung an	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Terns Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13.05.
Terns Pharmaceuticals, Inc. Announces Executive Changes	08.05.
Terns Pharmaceuticals, Inc. Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor Tern-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation	29.04.
Terns Pharmaceuticals, Inc. Appoints Melita Sun Jung as Chief Business Officer	10.04.
TERNS PHARMACEUTICALS, INC. : UBS persiste à l'achat	27.03.
TERNS PHARMACEUTICALS, INC. : JMP Securities toujours à l'achat	18.03.
TERNS PHARMACEUTICALS, INC. : BMO Capital optimiste sur le dossier	15.03.
Terns Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14.03.
Terns Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	14.03.
Terns Pharmaceuticals Gets Orphan Drug Label for Chronic Myeloid Leukemia Treatment Candidate	11.03.
Terns Pharmaceuticals, Inc. Appoints Amy Burroughs as Chief Executive Officer	07.02.
Terns Pharmaceuticals, Inc. Appoints Amy Burroughs as Member of Board of Directors	07.02.
TERNS PHARMACEUTICALS, INC. : Jefferies & Co. à l'achat	18.01.
TERNS PHARMACEUTICALS, INC. : HC Wainwright neutre sur le dossier	10.01.
TERNS PHARMACEUTICALS, INC. : Mizuho Securities toujours positif	27.11.
Terns Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14.11.
Terns Pharmaceuticals, Inc. Announces First Participant Dosed in Phase 1 Clinical Trial of TERN-601 Oral GLP-1 Receptor Agonist for Treatment of Obesity	02.11.
TERNS PHARMACEUTICALS, INC. : HC Wainwright maintient son opinion neutre	10.08.23
TERNS PHARMACEUTICALS, INC. : Opinion positive de Mizuho Securities	09.08.23
Terns Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	08.08.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Terns Pharmaceuticals, Inc.

Aktien

A2QNWR

US8808811074

TERN

Andere Sprachen

Filter